Genetic engineering of mesenchymal stromal cells for cancer therapy: turning partners in crime into Trojan horses
Innovative Surgical Sciences · 2016
DOI: 10.1515/iss-2016-0005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innovative Surgical Sciences, 2016. Verfasst von Hanno Niess und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral, Transplantation and Vascular Surgery, Hospital of the University of Munich, Munich, Germany. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 236 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Mesenchymal stromal cells (MSCs) are adult progenitor cells with a high migratory and differentiation potential, which influence a broad range of biological functions in almost every tissue of the body. Among other mechanisms, MSCs do so by the secretion of molecular cues, differentiation toward more specialized cell types, or influence on the immune system. Expanding tumors also depend on the contribution of MSCs to building a supporting stroma, but the effects of MSCs appear to go beyond the mere supply of connective tissues. MSCs show targeted “homing” toward growing tumors, which is then followed by exerting direct and indirect effects on cancer cells. Several research groups have developed novel strategies that make use of the tumor tropism of MSCs by engineering them to express a transgene that enables an attack on cancer growth. This review aims to familiarize the reader with the current knowledge about MSC biology, the existing evidence for MSC contribution to tumor growth with its underlying mechanisms, and the strategies that have been developed using MSCs to deploy an anticancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General, Visceral, Transplantation and Vascular Surgery, Hospital of the University of Munich, Munich, Germany.
- Department of General, Visceral and Cancer Surgery, Hospital of the University of Cologne, Cologne, Germany.
- Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universitaet Muenchen, Arbeitsgruppe Klinische Biochemie, Munich, Germany.
Zitieren
APA
Niess, H., Thomas, M. N., Schiergens, T. S., Kleespies, A., Jauch, K. W., Bruns, C., Werner, J., Nelson, P. J., & Angele, M. K. (2016). Genetic engineering of mesenchymal stromal cells for cancer therapy: turning partners in crime into Trojan horses. Innovative Surgical Sciences. https://doi.org/10.1515/iss-2016-0005
Vancouver
Niess H, Thomas MN, Schiergens TS, Kleespies A, Jauch KW, Bruns C, et al. Genetic engineering of mesenchymal stromal cells for cancer therapy: turning partners in crime into Trojan horses. Innovative Surgical Sciences. 2016. doi:10.1515/iss-2016-0005
BibTeX
@article{Niess2016,
author = {Niess, Hanno and Thomas, Michael N and Schiergens, Tobias S and Kleespies, Axel and Jauch, Karl-Walter and Bruns, Christiane and Werner, Jens and Nelson, Peter J and Angele, Martin K},
title = {Genetic engineering of mesenchymal stromal cells for cancer therapy: turning partners in crime into Trojan horses},
journal = {Innovative Surgical Sciences},
year = {2016},
doi = {10.1515/iss-2016-0005}
}
EUVIMED